Idiopathic Pulmonary Fibrosis (IPF)

Trial Objective

GERD & IPFThe purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI). The study also will determine if stomach reflux or abnormal swallowing are associated with the progression of IPF.

Enrollment

New enrollment for this trial is temporarily paused

Who Can Participate

Individuals ages 40-95 who have been diagnosed with IPF may be eligible to participate.

Age: 40-95    Gender: Any Gender


Estimated Time Commitment

5 visits over a 6-month period, visits are every 3 months



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Cole Waliczek, Trial Coordinator

Cole Waliczek
303.398.2844

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Boehringer Ingelheim

Principal Investigators


Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at www.njhealth.org/coronavirus.


*
*
*
*